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One of the major limitations of the use of adeno-associated virus (AAV) as a tool for gene therapy is the difficulty in providing
sufficient quantities of the virus for pre-clinical and clinical trials. Here, we report a novel approach for amplifying AAV helper functions,
which mimics the normal replication of wild type (wt) AAV resulting in a high yield of AAV vectors. Cotransfection of replicating but
non-packaging AAV helper constructs in the presence of adenovirus (Ad) produces a high level of Rep and Cap proteins. Yield of AAV2/
GFP vector obtained from this helper DNA replication system was approximately 20-fold higher than traditional methods. Molecular
analysis suggested that virus yield was associated with capsid protein production. The transfection ratio was optimized using these novel
helper constructs, resulting in an additional 2-fold increase in vector yield without presence of replication competent AAV (rcAAV). This
strategy supports development of AAV packaging systems that retain normal virus replication capability without helper virus
encapsidation.
D 2005 Elsevier Inc. All rights reserved.
Keywords: Replication; AAV; YieldAdeno-associated virus type (AAV) is a human parvovi-
rus with a single-stranded DNA genome of approximately
4.68 kb. AAV has increasingly become an important gene
therapy vector, largely because wild-type AAV (wtAAV) is
not associated with any known human diseases and the viral
genome has the capability to recombine site-specifically into
the human genome at chromosome 19 qter13.4. Recombi-
nant AAV (rAAV) genomes appear to persist in vivo pri-
marily as episomes and are capable of long-term transgene
expression (Schnepp et al., 2003). The lack of cell-mediated
immune responses to rAAV transduced cells is another key
reason for prolonged gene expression in vivo (Xiao et al.,
1996). Additionally, rAAV can infect dividing and non-
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E-mail address: RJS@med.unc.edu (R.J. Samulski).liver, brain and retina (Samulski et al., 1999; Stilwell et al.,
2003). Phase I studies using AAV have demonstrated safe
and persistent expression that is consistent with pre-clinical
studies (Hildinger and Auricchio, 2004; Monahan and
Samulski, 2000; Manno et al., 2003).
rAAV vectors are generally produced by cotransfection
of the rAAV vector plasmid and the helper plasmid coding
AAV rep and cap in the presence of a helper virus infection
(Samulski et al., 1989). Several recent improvements to
rAAV production have been reported such as using stable
cell lines that contain a subset of the required viral genes,
introducing AAV or the vector genome into producer cells
via chimeric viral vectors, or by eliminating the need for
helper virus infection through the use of cloned adenovirus
genes (Clark et al., 1995; Conway et al., 1999; Feudner et
al., 2001; Gao et al., 1998; Inoue and Russell, 1998; Liu et
al., 1999; Matsushita et al., 1998; Qiao et al., 2002a, 2002b;
Sollerbrant et al., 2001; Xiao et al., 1998; Zhang et al.,
1999). Recently, Urabe et al. (2002) proposed using
baculovirus as an alternative approach for producing high005) 10–21
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large-scale production concerns. However, most research
laboratories invest in optimizing vector cassettes as well as
testing novel serotypes, which can be extremely laborious
when establishing production cell lines (4–6 months) or
recombinant viral packaging strategies. Additionally, in
most cases, the production of rAAV is relatively inefficient
when compared with the number of particles generated
during a replicative wild-type virus infection. Under opti-
mized conditions, the transient transfection procedure can
yield a virus titer up to 1010 transducing units (TU) of rAAV
per milliliter, which represents approximately 50–150 TU
produced per transfected cell (Samulski et al., 1999). In
contrast, wtAAV generates 1000–5000 TU per cell (Samul-
ski et al., 1999). One major limitation of practical rAAV
application has been the failure of current transient pack-
aging systems to support sufficient amplification and
expression of AAV rep and cap gene products during the
vector packaging process. In order to improve the expres-
sion of Rep and Cap proteins, alternative replication systems
have been exploited. Recombinant adenovirus (rAd) vectors
carrying AAV helper functions have not been successful in
rAAV vector production because AAV Rep proteins inhibit
Ad replication. In order to address the need to amplify AAV
helper functions for optimum rAAV vector production,
inducible cell lines have been tested. Inducible amplification
of chromosomal loci containing the simian virus 40 (SV40)
replication origin in cells that express the SV40 large T
antigen has been used to produce titers of virus 10 times
higher than those produced by transfection methods. Virus
produced in this manner is also apparently free of
replication-competent AAV (rcAAV) (Inoue and Russell,
1998). Stable cell lines that have shown marked improve-
ment in vector production all correlate with an uncharac-
terized Rep-dependent amplification of helper genes from
the host chromosome (Blouin et al., 2004; Cao et al., 2002;
Chadeuf et al., 2000; Fan and Dong, 1997; Gao et al.,
2002b; Liu et al., 2000). All of these methods provide the
additional helper replication needed during vector produc-
tion. Unfortunately, the resulting amplification is not
controlled and does not mimic the amplification typically
seen with wtAAV infection. Here, we use a novel strategy
that mimics wtAAV replication when supplying AAV helper
genes rep and cap in trans to produce high titer rAAV
(Fig. 1a). This strategy is based on the findings that the ITRs
of AAV2 and AAV5 are only 60% identical and the rep
from one serotype cannot initiate replication from the ITR of
the other (Chiorini et al., 1999a, 1999b). In this system, the
rep and cap genes from AAV2 are inserted between two
ITRs from AAV5 and replication is supported by the
addition of plasmids expressing type 5 Rep proteins. In
turn, the type 2 Rep78 protein induces the replication of the
rAAV vector carrying AAV2 ITRs, and Rep 52 can
efficiently help to package this template into type 2 virions
(Fig. 1a). When tested, this approach resulted in rAAV
production 10- to 20-fold higher than traditional methodsthat rely solely on the initial input amount of AAV helper
constructs (Xiao et al., 1998).
A potential drawback with the use of serotype-specific
replicating AAV helper constructs is the potential to cross
package helper genomes into vector particles. To avoid
production of replication-competent AAV particles through
non-homologous recombination between serotype-specific
helper plasmids (Allen et al., 1997; Cao et al., 2000; Grimm
et al., 1998; Wang et al., 1998), we used the intron insertion
mutant described by Cao et al. (2000) to increase the size of
the AAV2 rep+cap cassette 2.35 kb above wild type
packaging limits. While this modification had no effect on
the amount of vector produced, it completely eliminated the
presence of rcAAV. This study demonstrates that a sig-
nificant increase in rAAV yield can be achieved by utilizing
serotype-specific ITRs for replicating AAV helper con-
structs that more closely mimic the natural infection scheme
of wtAAV.Results
Efficient replication of AAV2 rep and cap genes in the
presence of pREP5 and adenovirus
To mimic replication conditions utilized by wtAAV for
productive infection, we first constructed the plasmid pTR5/
AAV2 with the rep and cap genes from AAV2 inserted
between ITRs from AAV5 (Fig. 1b). To initiate replication
of this hybrid plasmid, Rep protein from AAV5 was
provided in a separate expression construct, pRep5. Forty-
eight hours after cotransfection of 293 cells using pTR5/
AAV2 with pRep5 in the presence of adenovirus, low-
molecular weight DNA was recovered. The presence of
AAV replicating templates was determined by Southern blot
analyses. To differentiate the input plasmids from newly
replicated DNA, Hirt DNA was digested with DpnI
endonuclease. AAV2 rep and cap helper plasmids were
not replicated when only Rep5 or adenovirus was added
singly (Fig. 2, lanes 10 and 11). However, in the presence of
all required components (Rep5 and Ad), the AAV2 rep and
cap helper plasmids were efficiently rescued and replicated
(Fig. 2 lane 12). Only those constructs carrying the type 5
ITR were able to replicate in the presence of type 5 Rep
protein, which is consistent with published studies. Repli-
cation of these hybrid substrates was identical to wtAAV
both in yield and size (Fig. 2 lane 12). In order to reduce the
risk of cross encapsidation of replicating helper constructs,
we expanded the genome size by 2.35 kb above wtAAV
using an intron approach described by Cao et al. (2000).
Plasmid pTR5/AAV2/INS was constructed, in which a h-
850 bp globin intron with a 1.5-kb lambda DNA fragment
was inserted at position 654 of the AAV2 genome (Fig. 1b).
This modification increased the total genome size between
the two AAV5 ITRs to 6.8 kb, which is 2 kb beyond normal
AAV2 packing limits. Cotransfection of pTR5/AAV2/INS
Fig. 1. (a) Strategy of helper DNA replication system to make rAAV virus. Step 1, AAV5 rep genome is driven by native p5 promoter to express REP5 protein.
Step 2, REP5 protein interacts with AAV5 TR to initiate AAV2 helper genome (Rep and Cap genes) replication and induce REP2 and CAP2 expression. Step3,
REP2 protein interacts with AAV2 TR of vector to initiate vector replication and helps package vector genome into capsids to form virions. (b) Diagram of
plasmid constructs and PCR strategy for analyzing structures of AAV species. See Materials and methods for details. Primers are shown as arrows. Primers a, b,
c and d are located at ITR2, rep2, ITR5 and rep5 genes, respectively.
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and amplification of the oversized replicating AAV helper
construct (6.8 kb) (Fig. 2 lane 16).
Rep and Cap expression from replicating templates
Next, we compared the production of the Rep and Cap
proteins of AAV2 from replicating and non-replicating
substrates using western blot analysis. As described
previously, AAV helper plasmid pXX2 generates fewer
Rep78/68 proteins than wtAAV2 plasmid pSSV9, withRep52/40 accumulating and representing the majority of
Rep proteins expressed in the presence of Ad (Fig. 3a lane
2). Under non-replicating conditions for pTR5/AAV2, the
ratio of Rep78/68 to Rep 52/40 was similar to that of pSSV9
in the presence of adenovirus (Fig. 3a lane 3 and lane 1,
respectively). All Rep protein expression increased when
pRep5 was supplied in trans (Fig. 3a lane 4). Surprisingly
when the 2.35-kb intron was inserted into position 654 of
the AAV2 genome, the pattern of Rep protein expression
was dramatically changed (Fig. 3a lane 5). The ratio of
Rep78/68 to Rep52/40 with pTR5/AAV2/INS was signifi-
Fig. 3. Western blot analysis of rep2 and cap2 gene expression. 293 cells
were transfected with 5 Ag of different helper plasmids with or without 5 Ag
pRep5 in the presence of adenovirus. 48 h later, cells were harvested and
10 Al of each cell lysate were separated by PAGE (10% polyacrylamide),
and transferred to a methylcellulose membrane. Western blot analysis was
performed with the primary antibodies anti-Rep monoclonal antibody 1F11
(a) or anti-cap monoclonal antibody B1 (b), which recognize all four rep2
proteins or three cap proteins, respectively.
Fig. 2. Southern blot analysis of helper DNA replication. 5 Ag of helper
plasmids pTR5/AAV2 and pTR5/AAV2/INS were transfected into 293 cells
with or without 5 Ag pRep5 in the absence or presence of adenovirus
infection. Low molecular DNAwas recovered from the cells, digested with
DpnI, separated on 0.8% agarose gel and transferred to nylon membrane.
The membrane was hybridized with a 32p-labeled rep/cap probe made from
the 4.5-kb XbaI fragment of pTR5/AAV2.
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lane 5 and lane 3, respectively). These disparate levels were
nearly identical in pattern to that seen with the previously
published pXX2 helper, and strongly suggest that any
modifications to the large Rep coding sequence dramatically
influence protein expression level. Although the ratio varied
with the use of the intron construct, the expression of Rep
protein increased when Rep5 was supplemented in trans
(Fig. 3a lane 6). The same membrane used in western
analysis to determine Rep expression was used to evaluate
the profile of Cap protein expression. Consistent with
replication analysis, there were lower levels of VP1/VP2/
VP3 from AAV2 helper constructs pXX2, pTR5/AAV2 and
pTR5/AAV2/INS when only adenovirus was present (Fig.
3b, lanes 2, 3 and 5, respectively). The addition of pRep5
increased Cap protein expression significantly (Fig. 3b lanes
4 and 6). From these analyses, we have shown that the
ability to replicate the AAV2 helper genes results in
concomitant increase in Rep and Cap protein expression
that is similar to wtAAV (Figs. 3a and b lanes 4, 6 and 1).
Replication of AAV2 rep and cap genes increases rAAVyield
To investigate whether the replication of the AAV helper
rep and cap genes increases rAAV vector production, we
used a recombinant AAV2-EGFP construct as a vector
substrate and compared viral yields in the presence or
absence of the replicating helper constructs described above.
The transducing rAAV titer was assessed by GFP trans-
duction of 293 cells. Forty-eight hours post-transfection and
adenovirus co-infection, cells were harvested and subjected
to three cycles of freeze-thaw. Non-replicating helper
plasmids pTR5/AAV2 and pTR5/AAV2/INS produced
comparable titers of vector to previously described pXX2
(Fig. 4). The vector yield increased 10- to 20-fold when
helper constructs pTR5/AAV2 or pTR5/AAV2/INS wereFig. 4. The effects of helper DNA replication on rAAV2/GFP yields. 293
cells were cotransfected with 2.5 Ag pTRUFR and 2.5 Ag of different helper
plasmids with or without 2.5 Ag pRep5 in the presence of adenovirus at the
MOI of 2. 48 h later, cells were recovered and frozen/thawed three times.
Adenovirus was inactivated by a 30-min incubation at 56 8C. The
supernatant of cell lysates was used to infect 293 cells to determine the
transducing units (TU). The results were indicated as average value F
standard error from 4 different experiments.
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of pRep5 to pXX2 markedly reduced virus yield 10-fold
(Fig. 4). To examine the molecular mechanism of increased
virus yield in this helper replicating system, helper gene
expression and the replication of helper genomes or vector
genomes were assayed, as shown in Fig. 5. Virus production
is positively associated with helper genome replication (Fig.
5d), which resulted in higher helper protein (Rep and Cap)
expression (Figs. 5a and b), but not vector genome
replication (Fig. 5c).
WT-like virus is generated from plasmid pTR5/AAV2
Previous studies have demonstrated the transcapsidation
of type 5 TR in AAV2 virions (Chiorini et al., 1999b).
Based on these data, we expected pTR5/AAV2, but not
pTR5/AAV2/INS, to be encapsidated in type 2 shells. Using
PCR analysis, we assayed for transcapsidation of AAV
helper constructs as well as DNA recombinants that may
have been generated from these replicating helper and
vector constructs (Fig. 1b). The primers used to carry out
these analyses are described in Fig. 1b. After transfection of
pTR2-EGFP, pTR5/AAV2 and pRep5, the cell lysate was
used to infect 293 cells in the presence of Ad for
amplification of wt-like AAV virus. The Hirt DNA was
extracted after each cycle and used as the template in PCR
analysis. Our results showed the presence of AAV2 wt-like
recombinants (TR2/AAV2) after two passages of vector cell
lysate (Fig. 6a, lane 2 and 3). Compared to control wtAAV2
amplification, we estimated about 1000 TU of wt-like
recombinants after 3 cycles of cell passage (compare Fig. 6aFig. 5. The expression of viral proteins and the replication of helper DNA and trans
of each plasmid, 293 cells were collected and divided, aliquot of cells was suspend
the rep2 and cap2 genes. The other aliquot of cells was used to extract the low mo
EGFP using the probes rep2/cap2 and EGFP (a fragment of Bgl II), respectively.
Vector EGFP replication. (d) Helper DNA replication. Con: pSSV9 transfection, 1:
AAV2/INS, 6: pTR5/AAV2/INS+pRep5.lanes 2, 3 and 6–9). We also detected hybrid type 5 wt-like
recombinants (TR5/Rep5Cap2) packaged in AAV2 virion
shells, but only after hybridization of PCR materials (Fig. 6a
lanes 15–17, data not shown). This suggests a reduced
frequency of recombination events between Rep2 and Rep5.
As expected from previous studies, we were able to detect
transcapsidated TR5/AAV2 templates in type 2 virion shells
(Fig. 6a lanes 10–12).
Plasmid TR5/AAV2 with intron reduces the generation of
rcAAV particles
Previous studies have determined that an AAV2 genome
size above 5.5 kb results in little to no encapsidation (Dong
et al., 1996). Cao et al. (2000) used an intron approach to
increase the helper plasmid size to reduce wt-like replicating
helper encapsidation. The pTR5/AAV2/INS helper used in
these studies carried an insertion of 2.35 kb. When assaying
for wt-like recombinants (both type 2 and type 5) using
PCR-specific primers, we were unable to detect PCR
products from primers TR2/Rep2 and TR5/Rep5 (Fig. 6b,
lanes 4 to 6 and 23 to 25). The only PCR products observed
were amplified with primers from TR5 and Rep2 (Fig. 6b,
lanes 13–15). The size of the product obtained using those
primers indicates a deletion of the intron on the Rep2 coding
cassette, generating fragments similar in size to wt-like.
However, based on PCR band intensity, the production of
TR5/AAV2 virion templates gradually decreased in each
successive passage (Fig. 6b, lanes 13–15). This suggests
that a reduction in size in order to achieve efficient
encapsidation may result in virus with a compromisedgene in the vector production system. 48 hours after transfection with 2.5 Ag
ed in RIPA medium for Western blot analysis to examine the expression of
lecular DNA to measure the replication of helper DNA and vector transgene
(a) The expression of rep proteins. (b) The expression of cap proteins. (c)
pXX2, 2: pXX2+pRep5, 3: pTR5/AAV2, 4: pTR5/AAV2+pRep5, 5: pTR5/
Fig. 6. Detection of replication competent AAV by PCR method in the virus preparations with helper pTR5/AAV2 or pTR5/AAV2/INS. 1 ml of cell lysate
of virus preparation with helper pTR5/AAV2 or pTR5/AAV2/INS and pTR2-EGFP and pRep5 was used to infect 293 cells in the presence of adenovirus at
MOI of 5 to amplify the rcAAV for total 3 cycles. Hirt DNA was extracted for PCR assay after each cycle of amplification. Panel a: M: DNA molecular
marker, 1: 1st cycle’s DNA amplified with primers a/b; 2: 2nd cycle’s with primer a/b; 3: 3rd cycle’s with primer a/b; 4: Hirt DNA from negative control
with 293 cells only infected with adenovirus with primer a/b; 5: positive control with 1 ng pSSV9 with primer a/b; 6: 3rd cycle’s Hirt DNA infected with
1000 TU wtAAV2 amplified with primer a/b. 7: 3rd cycle with 100 TU wtAAV2 with primer a/b; 8: 3rd cycle with 10TU wtAAV2 with primer a/b; 9: 3rd
cycle with 1TU wtAAV2 with primer a/b; 10. 1st cycle of Hirt DNA transfected with pTR5/AAV2 amplified with primer c/b; 11: 2nd cycle with primer c/b;
12: 3rd cycle with primer c/b; 13: negative control with primer b/c; 14: 1 ng pTR5/AAV2 amplified with primer c/b; 15: 1st cycle with primer c/d; 16: 2nd
cycle with primer c/d; 17: 3rd cycle with primer c/d; 18: negative control; 19: 1 ng pTR5/AAV5 with primer c/d. Panel b: Primers a/b were used for
samples 1–12; primers c/b for samples 13–22; primer c/d for 23–30. Samples 1–3 were from the cycle 1–3 Hirt DNA transfected with pXX2 to make virus.
Samples 4–6, 13–15 and 23–25 from the cycle 1–3 Hirt DNA transfected with pTR5/AAV2/INS with pRep5 to make virus. Samples 7, 16 and 26 are
negative controls. Samples 8, 17 and 27 were 1 ng of plasmids pSSV9, pTR5/AAV2 and pTR5/AAV5, respectively. Samples 9–12 represent the Hirt DNA
from 3rd cycle infected with 1000, 100, 10 and 1TU wt AAV2, respectively. Samples 18–22 were 10, 1, 101, 102 and 103 pg plasmid pTR5/AAV2,
respectively. Samples 28–30 were 10, 1 and 101 pg plasmid pTR5/AAV5, respectively.
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efficiently nick TR5 sequences (Fig. 6b, lanes 13–15).
Optimizing vector ratio increases the vector production
As described above, we observed a 10-fold decrease in
vector yields from AAV helper plasmid pXX2 in the presence
of the Rep5 protein. This suggested that an excess of Rep
protein may be deleterious to optimum vector production. In
attempt to avoid this concern, we transfected different ratios
of pTR5/AAV2/INS to pRep5 with a fixed amount of vector
DNA template (2.5 Ag). Higher titers of vector were
generated when less replicating helper plasmid and pRepTR5
construct were used (Fig. 7). The optimal ratio (2.5:1:1) of
transgene to pRep5 to pTR5/AAV2/INS was determined,
which resulted in a 2- to 3-fold increase in titer over theFig. 7. The effect of optimal ratio of pRep5 plasmid to helper plasmid pTR5/AAV
error of three different experiments.standard ratio of 1:1:1. We also analyzed the replication of
helper genomes and vector transgenes when different ratios
of pRep5 to pTR5/AAV2/INS were used (Fig. 8). When the
concentration of helper plasmid was fixed, increasing
amounts of pRep5 resulted in more efficient replication of
helper construct pTR5/AAV2/INS (Fig. 8 panel c: lanes 1–3
and 4–6). Interestingly when 2.5 Ag of helper DNAwas used,
replication of transgene was increased by lowering the
amount of pRep5 DNA (Fig. 8, panel d, lanes 1–3). However,
when lower amount (1 Ag) of helper DNA was used, the
replication of transgene was similar regardless of the amount
of pRep5 DNA (Fig. 8, panel d, lanes 4–6). In addition, when
the pRep5 construct concentration was fixed (2.5 Ag), an
increase in helper plasmid negatively affected vector repli-
cation (Fig. 8, panel d: lane 1 vs. lane 4). It was implicated
that transgene replication did not correlate with increasing2/INS on vector yield. The data represented the average value F standard
Fig. 8. The expression of helper DNA rep and cap and replication of helper DNA and transgene GFP at different ratio of pRep5 and pTR5/AAV2/INS. Panel a,
the expression of Rep proteins; Panel b, the expression of cap proteins; Panel c, helper DNA replication; Panel d, the transgene replication. Panel e, plot of the
relationship between virus yield and rep/cap protein production or the replication of helper gene/vector gene. Con: Control with pSSV9. 1: the ratio of pRep5 to
pTR5/AAV2/INS for transfection is 2.5 Ag:2.5 Ag; 2: the ratio of pRep5 to pTR5/AAV2/INS for transfection is 1 Ag:2.5 Ag. 3: the ratio of pRep5 to pTR5/
AAV2/INS for transfection is 0.5 Ag:2.5 Ag. 4: the ratio of pRep5 to pTR5/AAV2/INS for transfection is 2.5 Ag:1 Ag. 5: the ratio of pRep5 to pTR5/AAV2/INS
for transfection is 1 Ag:1 Ag. 6: the ratio of pRep5 to pTR5/AAV2/INS for transfection is 0.5 Ag:1 Ag.
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e). The highest amounts of pRep5 and pAAV2/AAV2/INS
DNA input initiated the lowest replication of transgene EGFP
(Fig. 8, panel d, lane 1, panel e). The expression of rep and
cap was also examined. Rep2 and Cap2 expression was
enhanced with higher levels of pRep5 DNA input, which
seems to be positively associated with virus vector yield if the
inhibition effect of Rep proteins (rep2 + rep5) for virus
production is considered. Taken together, these data may
suggest that an optimal balance among the production of Rep/
Cap, virus yield, and the potential negative effect of Rep5 canbe achieved by carefully controlling input ratios that
subsequently respond to amplification and coordinated
expression of AAV2 Rep/Cap and rAAV DNA replication
and encapsidation (Fig. 7 and Fig. 8 panel e).Discussion
We have demonstrated that an AAV2 rep and cap helper
genome can be efficiently amplified when using ITRs from
AAV5, with rep5 supplied in trans. Replication of the helper
C. Li, R.J. Samulski / Virology 335 (2005) 10–21 17genes correlated with increased AAV2 Rep and Cap protein
production, which in turn acted positively on rAAV2 vector
genomes replicating and packaging similarly to a wt AAV
infection. Using this system, we observed a 10- to 20-fold
increase in vector production when compared to established
methods (Xiao et al., 1998). Insertion of an intron into the
AAV2 rep gene dramatically decreased the production of
rcAAV particles without decreasing the titer of rAAV
production. We also demonstrated that the optimal ratio of
vector to Rep5 to AAV2 helper plasmids is 2.5:1:1.
Among the 9 serotypes of AAV, AAV5 is unique in that it
is the only dependent parvovirus originally isolated from a
patient sample instead of from laboratory stocks of
adenovirus (Bantel-Schaal and zur Hausen, 1984; Georg-
Fries et al., 1984). Similarity between AAV2 rep ORF and
the rep sequences from serotypes 1, 3 and 4 suggests that
AAV5 rep is more divergent (90% and 67% homologous,
respectively) (Chiorini et al., 1997; Gao et al., 2002a, 2004;
Muramatsu et al., 1996; Rutledge et al., 1998; Srivastava et
al., 1983; Xiao et al., 1999). In addition to divergency at the
protein level, the ITR sequence of AAV5 is only 58%
identical to AAV2’s ITR sequence (Chiorini et al., 1999a,
1999b; Srivastava et al., 1983). Although the rep binding
element (RBE) motif repeat of GAGC/T is conserved in the
ITRs of AAV5 and AAV2, the downstream terminal
resolution site (trs) sequence has only weak homology
between the two serotypes and a different spacing between
these elements (18 bp and 13 bp, respectively) (Chiorini et
al., 1999a, 1999b; Srivastava et al., 1983). In vitro
replication experiments determined that trans complemen-
tation does not occur at the level of DNA replication
between the respective Rep proteins and the divergent ITR
sequences, although these proteins will bind to either ITR
with similar efficiency (Chiorini et al., 1999a). Using these
features, we designed AAV2 helper constructs with type 5
ITR (pTR5/AAV2) that could rescue and replicate only in
the presence of AAV5 Rep protein in Ad co-infected cells
(Fig. 2). In addition to selected amplification of the AAV2
hybrid helper construct in the presence of Rep5, we
observed that the type 2 Rep and Cap protein patterns were
similar to that of wtAAV2 infection. Recent studies
characterizing high titer packaging cell lines have deter-
mined that the integrated rep and cap coding sequences are
typically amplified from the host chromosome by an
unknown mechanism (Blouin et al., 2004; Chadeuf et al.,
2000; Liu et al., 2000). Consistent between our study and
those of high titer packaging cell lines is the ability to
amplify the AAV helper genes rep and cap. Using the
replicating-dependent AAV helper DNA system described
in this study, we obtained about 1000–2000 TU/cell. This
resulted in a 10- to 20-fold increase over non-replicating
helper pTR5/AAV2 or pXX2.
Further characterization of this AAV production system
determined that AAV2 DNA can be packaged into AAV5
capsids, although the Rep5 protein is not able to nick TR2 to
initiate replication (Chiorini et al., 1999a, 1999b). We alsofound that AAV5 DNA can be packaged by AAV2 capsids
(data not shown). Thus, pTR5/AAV2 can be packaged into
AAV2 capsids to make recombinant virus in the replication
system. The presence of this kind of recombinant virus was
demonstrated when 293 cells were infected with vector
preparations from three cycles of virus passaging. TR5/
AAV2 genome containing viruses were detected after 3
passages by PCR analysis with one primer on TR5 and
another primer on Rep2. Viruses with this type of genome
are replication deficient, so more attention should be paid to
replication competent virus production through either
homologous or non-homologous recombination (Allen et
al., 1997; Grimm et al., 1998; Wang et al., 1998). Since
pTR5/AAV2 contains the full genome of AAV2, minus the
ITRs, and there is 58% homology between ITRs from
AAV5 and AAV2, as well as 67% homology between the
rep2 and rep5 genes, there is a possibility of homologous
recombination to form virus with TR2/AAV2 genome when
pTR5/AAV2 is transfected into cells with a transgene
cassette containing ITRs from AAV2 (Chiorini et al.,
1999b; Srivastava et al., 1983). Several investigations have
found that 0.0001%–10% of rcAAV can be produced
through the non-homologous recombination between helper
and transgene cassettes in the preparations of vectors using
traditional methods (Allen et al., 1997; Cao et al., 2000;
Wang et al., 1998). In the present study, the existence of
rcAAVs was detected by PCR amplification of the low
molecular weight DNA from the infection of rAAV vectors
and adenovirus. In the PCR system, the forward primer
comes from an ITR and the reverse primer is derived from a
rep gene sequence. This assay is quite sensitive, and has
previously been used to show that as little as one TU can be
detected in this way (Cao et al., 2000; Clark et al., 1999;
Gao et al., 1998). In our experiment, as a standard control,
10 TU wtAAV2 can be amplified by PCR from three cycles
of virus passaging in 293 cells. In addition, approximately
500 copies of pTR5/AAV2 and 5000 copies of pTR5/AAV5
were detectable using this PCR method. This assay requires
the rcAAV to possess both functional ITRs and an intact rep
gene. All three kinds of rcAAV (TR5/AAV2, TR2/AAV2
and TR5/Rep5cap2) were found in the amplified PCR
products following transfection with pTR2-EGFP, pTR5/
AAV2 and pRep5, which indicates that the recombination
may occur between rep2 and rep5, TR2 and TR5, or AAV2
repcap and vector EGFP.
Some groups have attempted to solve the rcAAV
production problem when making rAAV by modifying the
TR2 or rep2 genome or by splitting rep and cap into
different constructs. Wang et al. reported that the 10
nucleotides in the AAV D sequence distal to viral hairpin
structures are involved in recombination events leading to
rcAAV generation. They further suggest that the first 10
nucleotides in the D sequence proximal to the AAV hairpin
structures are essential for successful replication and
encapsidation of the viral genome (Wang et al., 1998).
Following from those conclusions, the combined use of
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sequence and helper plasmids lacking the adenovirus ITRs
led to complete elimination of replication-competent
wtAAV-like particles in recombinant vector stocks (Wang
et al., 1998). This contribution is significant with respect to
eliminating rcAAV; however, there is concern that this
alteration may influence the level of vector replication and
efficiency of vector packaging. A second approach deve-
loped to control rcAAV production uses heterologous
promoters for driving the rep and the cap genes (Allen et
al., 1997; Flotte et al., 1995). However, with this method,
rcAAV particles can still be detected in large-scale
preparations (Allen et al., 1997; Flotte et al., 1995). Splitting
the rep gene and the cap gene into different vectors is yet
another approach to reducing rcAAV production. Establish-
ing AAV rep and cap cell lines may significantly reduce the
generation of rcAAV (Gao et al., 1998). This logic is based
on the fact that considerably lower copies of integrated
helper genome are available for recombination. Generally,
these approaches, while successful in reducing rcAAV, also
resulted in lower titer of rAAV. New improvements in
packaging cell lines have suggested that this approach is
clearly viable for high titer, scalable production. One
advantage of the system described in this study is the fact
that many labs rely on a transient vector production system
as the means to define the final vector cassette to use in
establishing a packaging cell line. We feel this replicating
helper system enhances the ease of establishing optimized
AAV vectors for preclinical studies. Recently, Cao et al.
(2000) explored a new approach to reduce the generation of
rcAAV particles using intron-mediated mutagenesis of the
AAV genome. The additional intron in the AAV coding
region sufficiently increased the AAV genome to a size
beyond the packaging capacity and effectively reduced the
potential of generating rcAAV particles (Cao et al., 2000;
Dong et al., 1996). No effect on the efficiency of the helper
plasmid to support rAAV replication and packaging was
observed in these experiments. We used the same approach
by inserting the 850 bp h-globulin intron with 1.5 kb
lambda DNA fragment into the rep gene of pTR5/AAV2 at
position 654 to construct pTR5/AAV2/INS. A primary
difference was the ability to replicate the pTR5/AAV2/INS
helper construct in trans using pRep5 expression. The
transgene of pTR5/AAV2/INS effectively replicated after
cotransfection with pRep5 in the presence of adenoviruses.
However, the expression of rep78 and rep68 was decreased,
consistent with the finding of Cao et al. (2000) who
suggested that the 1.5-kb lambda DNA inserted into the
rep gene inadvertently disrupted the efficacy of the intron.
Previous studies have suggested that a reduction of rep78/68
protein expression is associated with an increase of vector
yield (Li et al., 1997). In our experiments, pTR5/AAV2/INS
can induce yields of vectors similar to pTR5/AAV2 helper.
The primary advantage of the INS modified helper is the
dramatic reduction in rcAAVs. However, we did observe
cross packaging of hybrid-virions that were replication-deficient (TR5/AAV2). It is not clear how to classify these
putative rcAAV since they are not a product of recombi-
nation and do not have ability to propagate in the vector
preparation.
With traditional plasmid transfection method, only 103 to
104 rAAV particles are generated per cell (Samulski et al.,
1999). Recently, Chadeuf et al. demonstrated that 10- to
100-fold more particles per cell could be produced with the
stable HeLa rep-cap cell line since the integrated rep-cap
genes were rapidly amplified (Blouin et al., 2004; Chadeuf
et al., 2000). However, the amplification of the rep-cap
genes is not controllable in the cell lines, and there is
potential risk of helper virus contamination, such adenovirus
and herpes. In this system, the rep and cap expression can
be regulated by input of pRep5 (Fig. 8e). With the
modulation of the ratio of helper plasmid to pRep5, the
virus yield can be further increased. In these experiments,
the vector yield is associated with rep2 and cap2 expression
and is not greatly influenced by helper plasmid replication
and/or vector replication when judged solely by final viral
yield (Fig. 8e). Although we did observe that the helper rep
and cap gene replication is dependent on the total input of
pRep5 and helper plasmid (Fig. 8e). However, the optimum
vector replication did not appear to be related with the
expression of Rep2 protein, replication of helper templates
and/or input of pRep5 (Fig. 8e). All of these observations
strongly suggest that the intricate relationship between trans
and cis-acting elements remains to be defined.
In conclusion, high-titer rAAV vectors generated by
replication of helper rep and cap genes that mimic the
production of wtAAV as described represents a novel
method for generating sufficient rAAV for preclinical and
small Phase I clinical trials. Increasing the size of the
replicating helper plasmid can dramatically decrease the
generation of rcAAV. The primary objective of this study
was to generate AAV Rep/Cap helper constructs that mimic
wtAAV protein levels during a productive infection. While
we have begun to approach this objective, room for further
improvement still exists. More importantly, using this
approach, we have begun to determine some of the critical
relationships between Rep/Cap protein levels, levels of
replicating viral templates and the efficiency of virion
production.Materials and methods
Plasmids
The plasmid XX2 is a previously published AAV
packaging plasmid containing the entire AAV coding
sequences with an ATG-to-ACG mutation in the start codon
of rep 78/68, reducing Rep78/68 protein synthesis (Xiao et
al., 1998). Its molecular size is 8.2 kb. pTR5/AAV2 was
constructed by inserting the entire AAV2 coding sequence
from an XbaI digestion of pSub201 between the two ITRs
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constructed by inserting the xba1 digested fragment con-
taining the insertion of 850 bp human h-globin intron and
1.5 kb lambda DNA fragment at position 654 of AAV
genome from pCLR1–1.5 kb between the two ITRs of
AAV5 (Fig. 2) (Cao et al., 2000). pTR5/AAV5 was
constructed by inserting the AAV5 rep and cap genes from
pAAV5-2 between two ITRs of AAV5. pAAV5-2 was
digested with PvuI and MscI to delete the cap gene, blunted
and ligated to clone pRep5 in which rep5 gene is driven by
native AAV5 p5 promoter. pAAV5-2 and p7D05 were
kindly provided by Dr. Kotin (NIH), pCLR1-1.5 was a
generous gift from Dr. Xiao (University of Pennsylvania).
Viruses and cells
rAAV was made by calcium phosphate cotransfection
methods as described previously (Xiao et al., 1996). 1  106
human 293 cells were seeded on 10 cm plate 24 h before
transfection in Dulbecco’s Modified Eagle’s medium
(DMEM) (Gibco) containing 10% fetal bovine serum
(FBS) (Gibco) with streptomycin and penicillin. The cells
were refreshed with 10 ml DMEM containing 10% FBS
without antibiotics 1–2 h before transfection. Plasmids were
dissolved in 0.5 ml of 0.25 M CaCl2 and then quickly mixed
with 0.5 ml of 2 HBS buffer (50 mM HEPES, 280 mM
NaCl, 1.5 mM NaHPO4 [pH 7.07]). The DNA precipitate
was slowly added to the cells. Meanwhile the cells were
infected with Ad5 (dl309) at a multiplicity of infection
(MOI) of 2. Forty-eight hours after transfection, the cells
were collected and divided into three aliquots. One aliquot
of cells and media was subjected to three cycles of freeze–
thaw and briefly centrifuged to remove cell debris, heated at
56 8C for 30 min to inactivate the Ad and stored at 20 8C
before use. The other aliquots of cells were used for Hirt
DNA extraction and Western blot of Rep and Cap proteins.
Assay of DNA replication
DNA was recovered from transfected cells by Hirt
extraction with slight modifications (Hirt, 1967). The cell
pellet from 1/3 of a 10-cm plate 293 cells was resuspended
in 728 Al of suspension buffer (20 mM Tris–HCl, 20 mM
EDTA[pH 8.0]) and lysed by adding 46 Al of 10% sodium
dodecyl sulfate (SDS). The cell lysate was mixed with 218
Al of 5 M NaCl, placed overnight at 4 8C, and centrifuged at
15000 rpm at 4 8C for 30 min. The supernatant was
harvested and extracted with phenol/chloroform, and
chloroform. Low-molecular weight DNA was precipitated
by the addition of an equal volume of isopropranol, rinsed
with 70% ethanol, and redissolved in 50 Al of TE buffer
(10 mM Tris–HCl, 1 mM EDTA [pH 8.0]) containing 100
Ag/ml of DNase-free RNase. The DNA was digested with
DpnI (New England Biolabs) and separated on a 0.8%
agarose gel. DNA was transferred to a nylon membrane.
Southern blot analysis was performed with a 32p-labeledprobe by using a random primer kit (Boehringer Mannheim
Biochemicals) as recommended by the manufacturer.
Western analyses of AAV Rep and Cap proteins
Western blots of AAV proteins were carried out by
previously published methods with modifications (Hunter
and Samulski, 1992). The cell pellet from 1/2 of a 10-cm
plate was lysed in 250 Al of RIPA buffer (10 mM Tris–HCl
[pH 8.2], 1% Triton X-100, 1% SDS, 150 mM NaCl). The
samples were separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) (10% polyacrylamide) and transferred to a
nitrocellulose membrane. After blocking with 10% nonfat
dry milk in TBS buffer (50 mM Tris–HCl [pH 7.5], 200 mM
NaCl) overnight at 4 8C, the membranes were incubated at
room temperature for 1 h with primary antibodies in TBS
containing 0.5% Tween-20. The primary antibody for Rep is
a mouse monoclonal antibody (1F11) that recognizes all
four Rep proteins; which is used at a 1:20 dilution. The
primary antibody for Cap proteins is B1 which recognizes
all three Cap proteins at a dilution of 1:100. Following
primary antibody incubation and washing, the membranes
were incubated with the secondary antibody, a goat anti-
mouse antibody conjugated with peroxidase (Sigma) at a 1:
2000 dilution, at room temperature for 1 h. All antibodies
were diluted in TBS buffer with 2% dry milk. After
washing, an enhanced chemiluminescence kit (Amersham)
was used for detection. In order to directly compare the
relationship between Rep and Cap protein expression, the
same membrane was used for both primary antibody
hybridization with the primary antibody of 1F11 or B1
after stripping the membrane with 0.2 M NaOH.
rcAAV assay and wtAAV titer determination
The infectious rcAAV or wt AAV was measured with
infection amplification assay. One ml of the cell lysate of
rAAV preparations was used to infect 293 cells of 10 cm
plate in the presence of adenovirus infection at the MOI of
5. The cells were harvested 48 h after infection and
subjected to 3 freeze–thaw cycles. Ad was inactivated by
heat treatment at 56 8C for 30 min. 1 ml cell lysate was used
to infect 293 cells with adenovirus for the second cycle of
amplification. Infection was repeated for a total of three
cycles and after each cycle of infection low molecular
weight DNA was extracted using the Hirt method. The
rcAAV was qualitatively determined by PCR analysis of
Hirt DNA. Three pairs of primers were used for this analysis
(Fig. 1b). The first pair of primers, primer a from AAV2 ITR
and prime b from AAV2 Rep were used to examine the wt
AAV2-like particles. The second pair, primer c from AAV5
ITR and primer b were used to detect the hybrid TR5/AAV2
virion production. The third pair, primer c and primer d from
AAV5 Rep were used to analyze the existence of wtAAV5-
like viruses. In the control experiment, wt AAV2 viruses
were used to infect 293 cells of 10 cm plate at different
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adenoviruses dl309 at MOI of 5. Three cycles later, Hirt
DNAwas extracted and PCR analysis was used to determine
the threshold of PCR sensitivity. The PCR primer positions
are indicated in Fig. 1b and sequences are shown as
following: a: AGAGAGGGAGTGGCCAACTCC; b: AT-
TCTCTTTGTTCTGCTCCTGCG; c: AGAGTGCCACAC-
TCTCAAGCAAGG; d: ACTGCACAAAGAATTTGGAQ
CTCCTGC. The sizes of PCR products with primers a/b,
c/b and c/d are 830 bp, 813 bp and 420 bp, respectively.
rAAV titer determination
The rAAV infectious titer was determined using green
fluorescent protein (GFP) as the reporter gene. Serial
dilutions of the rAAV preparations were used to infect
293 cells in the presence of adenovirus at an MOI of 5 for
24–48 h. Each dilution was performed in triplicate. The
average number of cells expressing GFP at the highest
dilution was accounted as the final titer.
Blot density assay
For Western blot and replication assay, the density of
Rep52, Cap VP3 and monomer in different samples were
measured with Personal densitometer SI (Molecular
Dynamics, Inc. Sunnyvale, CA). The value of samples
was calculated by comparison with the highest density in the
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